San Francisco, California--(Newsfile Corp. - November 26, 2021) - Hagens Berman urges CareDx, Inc. (NASDAQ: CDNA) investors to with significant losses to submit your losses now.
Visit: http://www.hbsslaw.com/investor-fraud/CDNA
Contact An Attorney Now: [email protected]
844-916-0895
CareDx, Inc. (CDNA) Investigation:
The investigation centers on the accuracy of CareDx's statements concerning its business practices, accounting, and public reporting, particularly pertaining to the company's kidney testing and phlebotomy services.
On Oct. 28, 2021, after the market closed, CareDx released Q3 2021 financial results in which the company disclosed that the U.S. Department of Justice ("DOJ") had recently served a civil investigatory demand requesting documents in connection with a False Claims Act investigation. The DOJ is investigating business practices related to CareDx's kidney testing and phlebotomy services. The company also disclosed that it received a subpoena from the U.S. Securities and Exchange Commission for similar issues as well as certain accounting and public reporting practices, and the company received an information request from an unnamed state agency.
"We're focused on investors' losses and whether CareDx engaged in making false claims concerning its kidney tests to federal health care programs," said Reed Kathrein, the Hagens Berman partner leading the investigation.
If you invested in CareDx and have significant losses, or have knowledge that may assist...
The Department of Justice has charged over 450 people in health care fraud schemes totaling a record $6.5 billion. A Coos Bay man was charged with conspiracy to commit health care fraud in connect...